The impact of the TailorX and RxPonder studies and the use of Oncotype Dx in clinical practice: A single Breast Cancer Center experience

被引：0
|
作者：
Nasikas, D. [1 ]
Fostira, F. [2 ]
Tsoulos, N. [3 ]
Fokianou, A. [1 ]
Kontogianni, P. [1 ]
Ntasiou, P. [1 ]
Xepapadakis, G. [1 ]
机构：
[1] IASO Hosp, Breast Clin 2, Athens, Greece
[2] NCSR DEMOCRITOS, Mol Diagnost Lab, Athens, Greece
[3] Genekor Med SA, Athens, Greece
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P152
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [11] The impact of the Oncotype Dx breast cancer assay in clinical practice: Systematic review and meta-analysis.
    Carlson, Josh John
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [12] Routine practice use of Oncotype Dx assay in French breast cancer patients
    Wassermann, J.
    Toledano, A.
    Gligorov, J.
    Conforti, R.
    Grapin, J. P.
    Benothman, S.
    Spano, J. P.
    Khayat, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S323 - S323
  • [13] Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial
    Mariotto, Angela
    Jayasekera, Jinani
    Petkov, Valentina
    Schechter, Clyde B.
    Enewold, Lindsey
    Helzlsouer, Kathy J.
    Feuer, Eric J.
    Mandelblatt, Jeanne S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (02): : 154 - 160
  • [14] Impact of Oncotype DX on chemotherapy assignment: a retrospective single-center study on female breast cancer patients
    Panousis, Dimitris
    Ntasiou, Panagiota
    Grosomanidis, Dimitris
    Chatzopoulos, Konstantinos
    Paraskevakou, Georgia
    Kontogianni, Panagiota
    Charitidou, Efstratia
    Xepapadakis, Grigoris
    JOURNAL OF BUON, 2017, 22 (05): : 1199 - 1208
  • [15] Re: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial
    Rossi, Paolo Giorgi
    Paci, Eugenio
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (03): : 318 - 319
  • [16] Oncotype DX Recurrence Score in Node Positive Patients in the Post-RxPONDER Era: A Single Institution Experience
    Han, Rachel
    Brogi, Edi
    El-Tamer, Mahmoud
    Morrow, Monica
    Wen, Hannah
    LABORATORY INVESTIGATION, 2024, 104 (03) : S167 - S169
  • [17] Erratum to: The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis
    Josh J. Carlson
    Joshua A. Roth
    Breast Cancer Research and Treatment, 2014, 146 : 233 - 233
  • [18] Comparison of Oncotype Dx and Mammprint in a community breast surgical practice: Implications from the MINDACT, TAILORx, and PROMIS Trials
    Maganini, Robert
    Altimari, Marc
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 445 - 446
  • [19] OUR FIRST EXPERIENCE OF ONCOTYPE DX IN EARLY BREAST CANCER
    Khawaja, S.
    Sharaiha, Y.
    Pitcher, S.
    Whelan, S.
    Brinkworth, E.
    Pudney, D.
    Moe, M.
    Rolles, M.
    Bertelli, G.
    Holt, S.
    ANNALS OF ONCOLOGY, 2011, 22 : 46 - 46
  • [20] The impact of the Oncotype DX recurrence score pathology-clinical (RSPC) on the predicted recurrence risk for node negative breast cancer patients: A cancer center experience
    Wexelman, Barbara A.
    Gallagher, Alexander
    Smith, Barbara L.
    Isakoff, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345